For instance, eculizumab and ravulizumab (ALXN210) are FDA approved for treating paroxysmal nocturnal hemoglobinuria.34,35 BB5.1 is a mouse analogue to eculizumab and ravulizumab, and future studies should examine the treatment effects of the combination therapy of BB5.1 and C3 inhibitors on TBI outcomes. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.